Abstract
The enhancer of zeste homolog 2 (EZH2) is upregulated and has an oncogenic role in several types of human cancer. However, the abnormalities of EZH2 and its underlying mechanisms in the pathogenesis of nasopharyngeal carcinoma (NPC) remain unknown. In this study, we found that high expression of EZH2 in NPC was associated closely with an aggressive and/or poor prognostic phenotype (P<0.05). In NPC cell lines, knockdown of EZH2 by short hairpin RNA was sufficient to inhibit cell invasiveness/metastasis both in vitro and in vivo, whereas ectopic overexpression of EZH2 supported NPC cell invasive capacity with a decreased expression of E-cadherin. In addition, ablation of endogenous Snail in NPC cells virtually totally prevented the repressive activity of EZH2 to E-cadherin, indicating that Snail might be a predominant mediator of EZH2 to suppress E-cadherin. Furthermore, co-immunoprecipitation (IP), chromatin IP and luciferase reporter assays demonstrated that in NPC cells, (1) EZH2 interacted with HDAC1/HDAC2 and Snail to form a repressive complex; (2) these components interact in a linear fashion, not in a triangular fashion, that is, HDAC1 or HDAC2 bridge the interaction between EZH2 and Snail; and (3) the EZH2/HDAC1/2/Snail complex could closely bind to the E-cadherin promoter by Snail, but not YY1, to repress E-cadherin. The data provided in this report suggest a critical role of EZH2 in the control of cell invasion and/or metastasis by forming a co-repressor complex with HDAC1/HDAC2/Snail to repress E-cadherin, an activity that might be responsible, at least in part, for the development and/or progression of human NPCs.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
265,23 € per year
only 5,30 € per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout





Similar content being viewed by others
References
Bachmann IM, Halvorsen OJ, Collett K, Stefansson IM, Straume O, Haukaas SA et al. (2006). EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. J Clin Oncol 24: 268–273.
Batlle E, Sancho E, Franci C, Dominguez D, Monfar M, Baulida J et al. (2000). The transcription factor snail is a repressor of E-cadherin gene expression in epithelial tumour cells. Nat Cell Biol 2: 84–89.
Boyer LA, Plath K, Zeitlinger J, Brambrink T, Medeiros LA, Lee TI et al. (2006). Polycomb complexes repress developmental regulators in murine embryonic stem cells. Nature 441: 349–353.
Cai MY, Tong ZT, Zheng F, Liao YJ, Wang Y, Rao HL et al. (2011). EZH2 protein: a promising immunomarker for the detection of hepatocellular carcinomas in liver needle biopsies. Gut 60: 967–976.
Camp RL, Dolled-Filhart M, Rimm DL . (2004). X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res 10: 7252–7259.
Cano A, Perez-Moreno MA, Rodrigo I, Locascio A, Blanco MJ, del Barrio MG et al. (2000). The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nat Cell Biol 2: 76–83.
Cao Q, Yu J, Dhanasekaran SM, Kim JH, Mani RS, Tomlins SA et al. (2008). Repression of E-cadherin by the polycomb group protein EZH2 in cancer. Oncogene 27: 7274–7284.
Cao R, Wang L, Wang H, Xia L, Erdjument-Bromage H, Tempst P et al. (2002). Role of histone H3 lysine 27 methylation in polycomb-group silencing. Science 298: 1039–1043.
Caretti G, Di Padova M, Micales B, Lyons GE, Sartorelli V . (2004). The polycomb Ezh2 methyltransferase regulates muscle gene expression and skeletal muscle differentiation. Genes Dev 18: 2627–2638.
Chen Y, Lin MC, Yao H, Wang H, Zhang AQ, Yu J et al. (2007). Lentivirus-mediated RNA interference targeting enhancer of zeste homolog 2 inhibits hepatocellular carcinoma growth through down-regulation of stathmin. Hepatology 46: 200–208.
Collett K, Eide GE, Arnes J, Stefansson IM, Eide J, Braaten A et al. (2006). Expression of enhancer of zeste homologue 2 is significantly associated with increased tumor cell proliferation and is a marker of aggressive breast cancer. Clin Cancer Res 12: 1168–1174.
Fandi A, Altun M, Azli N, Armand JP, Cvitkovic E . (1994). Nasopharyngeal cancer: epidemiology, staging, and treatment. Semin Oncol 21: 382–397.
Finnin MS, Donigian JR, Cohen A, Richon VM, Rifkind RA, Marks PA et al. (1999). Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature 401: 188–193.
Fujii S, Ochiai A . (2008). Enhancer of zeste homolog 2 downregulates E-cadherin by mediating histone H3 methylation in gastric cancer cells. Cancer Sci 99: 738–746.
He LR, Liu MZ, Li BK, Jia WH, Zhang Y, Liao YJ et al. (2010). High expression of EZH2 is associated with tumor aggressiveness and poor prognosis in patients with esophageal squamous cell carcinoma treated with definitive chemoradiotherapy. Int J Cancer 127: 138–147.
Herranz N, Pasini D, Diaz VM, Franci C, Gutierrez A, Dave N et al. (2008). Polycomb complex 2 is required for E-cadherin repression by the Snail1 transcription factor. Mol Cell Biol 28: 4772–4781.
Kidani K, Osaki M, Tamura T, Yamaga K, Shomori K, Ryoke K et al. (2009). High expression of EZH2 is associated with tumor proliferation and prognosis in human oral squamous cell carcinomas. Oral Oncol 45: 39–46.
Lee TI, Jenner RG, Boyer LA, Guenther MG, Levine SS, Kumar RM et al. (2006). Control of developmental regulators by polycomb in human embryonic stem cells. Cell 125: 301–313.
Lo KW, To KF, Huang DP . (2004). Focus on nasopharyngeal carcinoma. Cancer Cell 5: 423–428.
Matsukawa Y, Semba S, Kato H, Ito A, Yanagihara K, Yokozaki H . (2006). Expression of the enhancer of zeste homolog 2 is correlated with poor prognosis in human gastric cancer. Cancer Sci 97: 484–491.
Mimori K, Ogawa K, Okamoto M, Sudo T, Inoue H, Mori M . (2005). Clinical significance of enhancer of zeste homolog 2 expression in colorectal cancer cases. Eur J Surg Oncol 31: 376–380.
Muller J, Kassis JA . (2006). Polycomb response elements and targeting of polycomb group proteins in Drosophila. Curr Opin Genet Dev 16: 476–484.
Peinado H, Ballestar E, Esteller M, Cano A . (2004). Snail mediates E-cadherin repression by the recruitment of the Sin3A/histone deacetylase 1 (HDAC1)/HDAC2 complex. Mol Cell Biol 24: 306–319.
Raman JD, Mongan NP, Tickoo SK, Boorjian SA, Scherr DS, Gudas LJ . (2005). Increased expression of the polycomb group gene, EZH2, in transitional cell carcinoma of the bladder. Clin Cancer Res 11: 8570–8576.
Rao ZY, Cai MY, Yang GF, He LR, Mai SJ, Hua WF et al. (2010). EZH2 supports ovarian carcinoma cell invasion and/or metastasis via regulation of TGF-beta1 and is a predictor of outcome in ovarian carcinoma patients. Carcinogenesis 31: 1576–1583.
Satijn DP, Hamer KM, den Blaauwen J, Otte AP . (2001). The polycomb group protein EED interacts with YY1, and both proteins induce neural tissue in Xenopus embryos. Mol Cell Biol 21: 1360–1369.
Schwartz YB, Kahn TG, Nix DA, Li XY, Bourgon R, Biggin M et al. (2006). Genome-wide analysis of polycomb targets in Drosophila melanogaster. Nat Genet 38: 700–705.
Schwartz YB, Pirrotta V . (2007). Polycomb silencing mechanisms and the management of genomic programmes. Nat Rev Genet 8: 9–22.
Simon JA, Lange CA . (2008). Roles of the EZH2 histone methyltransferase in cancer epigenetics. Mutat Res 647: 21–29.
Simon JA, Kingston RE . (2009). Mechanisms of polycomb gene silencing: knowns and unknowns. Nat Rev Mol Cell Biol 10: 697–708.
Song LB, Li J, Liao WT, Feng Y, Yu CP, Hu LJ et al. (2009). The polycomb group protein Bmi-1 represses the tumor suppressor PTEN and induces epithelial-mesenchymal transition in human nasopharyngeal epithelial cells. J Clin Invest 119: 3626–3636.
Sudo T, Utsunomiya T, Mimori K, Nagahara H, Ogawa K, Inoue H et al. (2005). Clinicopathological significance of EZH2 mRNA expression in patients with hepatocellular carcinoma. Br J Cancer 92: 1754–1758.
Tiwari VK, McGarvey KM, Licchesi JD, Ohm JE, Herman JG, Schubeler D et al. (2008). PcG proteins, DNA methylation, and gene repression by chromatin looping. PLoS Biol 6: 2911–2927.
van der Vlag J, Otte AP . (1999). Transcriptional repression mediated by the human polycomb-group protein EED involves histone deacetylation. Nat Genet 23: 474–478.
Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C, Sanda MG et al. (2002). The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 419: 624–629.
von Burstin J, Eser S, Paul MC, Seidler B, Brandl M, Messer M et al. (2009). E-cadherin regulates metastasis of pancreatic cancer in vivo and is suppressed by a SNAIL/HDAC1/HDAC2 repressor complex. Gastroenterology 137: 361–371.
Wang L, Brown JL, Cao R, Zhang Y, Kassis JA, Jones RS . (2004). Hierarchical recruitment of polycomb group silencing complexes. Mol Cell 14: 637–646.
Wei WI, Mok VW . (2007). The management of neck metastases in nasopharyngeal cancer. Curr Opin Otolaryngol Head Neck Surg 15: 99–102.
Wilkinson F, Pratt H, Atchison ML . (2010). PcG recruitment by the YY1 REPO domain can be mediated by Yaf2. J Cell Biochem 109: 478–486.
Xie D, Sham JS, Zeng WF, Lin HL, Che LH, Wu HX et al. (2003). Heterogeneous expression and association of beta-catenin, p16 and c-myc in multistage colorectal tumorigenesis and progression detected by tissue microarray. Int J Cancer 107: 896–902.
Acknowledgements
We thank Dr Clifford W Welsch (Michigan State University) for his valuable comments and extensive edit for the paper. This work was supported by the Foundation of Guangzhou Science and Technology Bureau, China (2005Z1-E0131 to DX and HFK) and the 973 Project of China (2010CB912802 to HFK and 2010CB529400 to XWB and MCL).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary Information accompanies the paper on the Oncogene website
Rights and permissions
About this article
Cite this article
Tong, ZT., Cai, MY., Wang, XG. et al. EZH2 supports nasopharyngeal carcinoma cell aggressiveness by forming a co-repressor complex with HDAC1/HDAC2 and Snail to inhibit E-cadherin. Oncogene 31, 583–594 (2012). https://doi.org/10.1038/onc.2011.254
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/onc.2011.254
Keywords
This article is cited by
-
Hypoxia-activated XBP1s recruits HDAC2-EZH2 to engage epigenetic suppression of ΔNp63α expression and promote breast cancer metastasis independent of HIF1α
Cell Death & Differentiation (2024)
-
The role and application of transcriptional repressors in cancer treatment
Archives of Pharmacal Research (2023)
-
Long non-coding RNAs as the critical regulators of epithelial mesenchymal transition in colorectal tumor cells: an overview
Cancer Cell International (2022)
-
DAB2IP predicts treatment response and prognosis of ESCC patients and modulates its radiosensitivity through enhancing IR-induced activation of the ASK1-JNK pathway
Cancer Cell International (2022)
-
Navigating EMT with COMPASS and PRC2
Nature Cell Biology (2022)